Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04109586
Other study ID # REK 2017/2443
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 15, 2019
Est. completion date March 30, 2025

Study information

Verified date December 2023
Source Sunnaas Rehabilitation Hospital
Contact Hanne B Slettahjell, MSc
Phone 004748107330
Email hannebjorg.slettahjell@sunnaas.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized clinical controlled trial (RCT) to investigate the impact of a personalized nutritional intervention on functional and clinical outcomes the first year after traumatic spinal cord injury. The long term goal is to prevent gain of body fat mass and obesity.


Description:

Traumatic spinal cord injury (SCI) is a devastating injury resulting from critical incidents like falls, sports- and traffic accidents, demanding lifelong specialist health care services. A major challenge is the prevalence of obesity following metabolic alterations after SCI. Obesity hampers independence and mobility and has a negative impact on quality of life. Accumulation of adipose tissue is reported to be higher than in able-bodied, explaining the high risk of cardiometabolic disease in the SCI population. Food intake is the supreme variable in prevention of obesity after SCI, however there is a paucity in studies investigating nutrition as a measure to prevent and reduce comorbidity. Key questions that remains unanswered are how early adipose tissue accumulates, if nutritional manipulations can prevent obesity and how follow-up can help maintain a healthy lifestyle. In the present three-part started-up PhD-study, we use MRI techniques to quantify accumulation of adipose tissue in a cohort study the first year after SCI, test the efficacy of a nutrition intervention to prevent obesity in a randomized controlled trial, and finally, we will test the feasibility of guided online-support to promote a healthy lifestyle after discharge from in-patient rehabilitation. Successful results will be implemented in care-programs at our hospital for those with SCI and similar mobility impairments, with the aim of improving nutrition practice throughout the course of treatment


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date March 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Traumatic spinal cord injury - Levels C1-L2 - American Spinal Injury Association (ASIA) Impairments Scale (AIS) A-D Exclusion Criteria: - Glasgow Coma Scale score (GCS) equal to or lower than 13 - Below 18 years of age - Medical issues like impaired cognitive function, progressive disorders and co-morbidities.

Study Design


Intervention

Behavioral:
Personalized nutritional therapy
Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury

Locations

Country Name City State
Norway Sunnaas Rehabilitation Hospital Nesoddtangen Bjørnemyr

Sponsors (3)

Lead Sponsor Collaborator
Sunnaas Rehabilitation Hospital University of Copenhagen, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in fat-free mass Bioimpedance Analysis (BIA) will be used to determine body composition by measuring fat-free mass Change from Baseline to 12 months follow-up
Secondary Body weight Measuring body weight in kilograms (kg) Change from Baseline to 12 months follow-up
Secondary Independency in activities of daily living (ADLs) Spinal Cord Independence Measure (SCIM) III will be used to assess various activities of daily living (ADLs). SCIM III comprises 19 items divided into 3 subscales (self-care, respiration and sphincter management, and mobility). The total SCIM score range from 0 to 100, with the subscales weighted as follows: self-care: scored 0-20; respiration and sphincter management: scored 0-40; and mobility: scored 0-40. Scores are higher in patients that require less assistance or fewer aids to complete basic ADLs. Change from Baseline to 12 months follow-up
Secondary Change in adipose tissue Magnetic resonance imaging (MRI) scanning will be used to determine body composition by quantification of adipose tissues (visceral adipose tissue volume and abdominal subcutaneous adipose tissue volume) and muscle volumes. Change from Baseline to 12 months follow-up
Secondary Changes in Quality of life (QoL) International Spinal Cord Society QoL Basic Dataset. The QoL data set consists of 3 variables: ratings of satisfaction with general quality of life, satisfaction with physical health, and satisfaction with psychological health. All variables are rated on a Numeric Self-Rating Scale ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Changes from Baseline to 12 months follow-up
Secondary Change in albumin Fasted blood analysis of albumin g/dl Change from Baseline to 12 months follow-up
Secondary Change in fasting glucose Fasted blood analysis of fasting glucose (mmol/L) Change from Baseline to 12 months follow-up
Secondary Change in Creatinine Fasted blood analysis of creatinine umol/L Change from Baseline to 12 months follow-up
Secondary Change in Lipoprotein A1 Fasted blood analysis of Lipoprotein A1 (g/L) Change from Baseline to 12 months follow-up
Secondary Change in Lipoprotein B Fasted blood analysis of Lipoprotein B (g/L) Change from Baseline to 12 months follow-up
Secondary Change in folic acid Fasted blood analysis of folic acid (nmol/L) Change from Baseline to 12 months follow-up
Secondary Change in vitamin B12 Fasted blood analysis of vitamin B12 pmol/L Change from Baseline to 12 months follow-up
Secondary Change in Ferritin Fasted blood analysis of ferritin ug/L Change from Baseline to 12 months follow-up
Secondary Change in C-reactive protein (CRP) Fasted blood analysis of C-reactive protein mg/l Change from Baseline to 12 months follow-up
Secondary Change in Cholesterol Fasted blood analysis of total cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL) mmol/L Change from Baseline to 12 months follow-up
Secondary Change in Triglycerides Fasted blood analysis of triglycerides mmol/L Change from Baseline to 12 months follow-up
Secondary Change in C-peptid Blood analysis of insulin c-peptid pmol/L in a fasted state and 2 hours post oral glucose tolerance test Change from Baseline to 12 months follow-up
Secondary Change in vitamin 25-hydroxy-vitamin D3 Fasted blood analysis of 25-hydroxy-vitamin D3 (nmol/L) Change from Baseline to 12 months follow-up
Secondary Change in Glycated hemoglobin (HbA1c) Fasted blood analysis of HbA1c mmol/mol Change from Baseline to 12 months follow-up
Secondary Change in Cytokines: Interleukin-6 and -1, Tumor necrosis factor-a (TNF-a) Fasted blood analysis of Interleukin-6 and -1 Tumor necrosis factor-a (TNF-a) (pg/ml) Change from Baseline to 12 months follow-up
Secondary Change in isoprostanes (biomarkers of oxidative stress) Urine analyses of isoprostanes (ng/mg) (biomarkers of oxidative stress) Change from Baseline to 12 months follow-up
Secondary Change in cardiorespiratory fitness levels ml/kg/min Cardiorespiratory fitness levels will be determined by measuring peak oxygen uptake (VO2peak; ml/kg/min) during maximal exercise testing on a treadmill or ergometry cycle. Change from Baseline to 12 months follow-up
Secondary Change in cardiorespiratory fitness levels liter/min Cardiorespiratory fitness levels will be determined by measuring peak oxygen uptake (VO2peak; liter/min) during maximal exercise testing on a treadmill or ergometry cycle. Change from Baseline to 12 months follow-up
Secondary Change in fasting blood glucose level (mmol/Liter) Standardized oral glucose tolerance test (OGTT) will be used to measure the blood glucose level (mmol/Liter) 2 hours after intake of 75 grams glucose in a fasted state. Change from Baseline to 12 months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2